These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 26657087)

  • 21. Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration.
    Davit BM; Nwakama PE; Buehler GJ; Conner DP; Haidar SH; Patel DT; Yang Y; Yu LX; Woodcock J
    Ann Pharmacother; 2009 Oct; 43(10):1583-97. PubMed ID: 19776300
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The year's new drugs and biologics--2006.
    Graul AI; Sorbera LA; Bozzo J; Serradell N; Revel L; Prous JR
    Drug News Perspect; 2007; 20(1):17-44. PubMed ID: 17332898
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Extension of market exclusivity and its impact on the accessibility to essential medicines, and drug expense in Thailand: analysis of the effect of TRIPs-Plus proposal.
    Akaleephan C; Wibulpolprasert S; Sakulbumrungsil R; Luangruangrong P; Jitraknathee A; Aeksaengsri A; Udomaksorn S; Tangcharoensathien V; Tantivess S
    Health Policy; 2009 Jul; 91(2):174-82. PubMed ID: 19150741
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The trials and tribulations of repurposing metformin and other generic drugs for tuberculosis.
    Bloom BE
    Pharm Pat Anal; 2016; 5(2):101-5. PubMed ID: 26889918
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Exclusivity of data in drug registration files and Israel's international status with regard to intellectual property rights protection].
    Lipschitz Y; Tamir O; Shemer J
    Harefuah; 2004 Dec; 143(12):845-8, 912. PubMed ID: 15666700
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The regulatory system in europe with special emphasis on allergen products.
    Lorenz AR; Luttkopf D; Seitz R; Vieths S
    Int Arch Allergy Immunol; 2008; 147(4):263-75. PubMed ID: 18648190
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The interaction between intellectual property and drug regulatory systems: global perspectives.
    Madden EA
    IDrugs; 2007 Feb; 10(2):116-20. PubMed ID: 17285464
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Generic medicines: issues and relevance for global health.
    Rana P; Roy V
    Fundam Clin Pharmacol; 2015 Dec; 29(6):529-42. PubMed ID: 26405851
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Non-clinical Post-Marketing Commitments for newly licenced pharmaceuticals.
    Reeve LM
    Regul Toxicol Pharmacol; 2009 Nov; 55(2):181-7. PubMed ID: 19589365
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Old active ingredients in new medicinal products: is the regulatory path coherent with patients' expectations?
    Minghetti P; Musazzi UM; Casiraghi A; Rocco P
    Drug Discov Today; 2020 Aug; 25(8):1337-1347. PubMed ID: 32485225
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [The use of nanotechnology in medicinal products in the light of European Union law].
    Jurewicz M
    Pol Merkur Lekarski; 2014 Dec; 37(222):369-72. PubMed ID: 25715580
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Better medicines for children: European measures].
    van den Berg H; Taminiau JA
    Ned Tijdschr Geneeskd; 2008 Jul; 152(27):1537-40. PubMed ID: 18681365
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Regulatory exclusivities for medicinal products for human use in the EU.
    Schoonderbeek C; Jong B
    Pharm Pat Anal; 2016; 5(1):5-8. PubMed ID: 26674744
    [No Abstract]   [Full Text] [Related]  

  • 34. Regulatory considerations and intellectual property rights of repurposed drugs.
    Afzaal H; Waseem T; Saeed A; Noori FA; Obaidullah ; Babar MM
    Prog Mol Biol Transl Sci; 2024; 205():357-375. PubMed ID: 38789186
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Regulatory structures for gene therapy medicinal products in the European Union.
    Klug B; Celis P; Carr M; Reinhardt J
    Methods Enzymol; 2012; 507():337-54. PubMed ID: 22365782
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Innovating by developing new uses of already-approved drugs: trends in the marketing approval of supplemental indications.
    DiMasi JA
    Clin Ther; 2013 Jun; 35(6):808-18. PubMed ID: 23726388
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of intellectual property rights in treatment access: challenges and solutions.
    't Hoen E; Passarelli CA
    Curr Opin HIV AIDS; 2013 Jan; 8(1):70-4. PubMed ID: 23201855
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Projecting future drug expenditures--1992.
    Ensor PA
    Am J Hosp Pharm; 1992 Jan; 49(1):140-5. PubMed ID: 1570858
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Requirements on efficacy of herbal medicinal products.
    Claeson P
    J Ethnopharmacol; 2014 Dec; 158 Pt B():463-6. PubMed ID: 25043782
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [European Agency for the Evaluation of Medicinal Products: five years experience].
    Sauer F
    Bull Mem Acad R Med Belg; 2000; 155(5-6):254-8; discussion 259-62. PubMed ID: 11304960
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.